NCT01338818
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
See it on ClinicalTrials.gov ↗298 people
46.3%
53.7%
138 womenmiddle line = equal numbers160 men
- Phase
- PHASE3
- Paid for by
- Novartis Pharmaceuticals
- Finished
- 2013-02
- Health conditions
- Attention Deficit/Hyperactivity Disorder
- Who could join
- Anyone
- Ages
- 18 Years – 60 Years
- Average age
- mean 36.3 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 60 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnant women.”
- No seizures
Women with epilepsy or past seizures were turned away.
“Patients who developed seizures during the core study.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments.”
Study titles and rules are shown in their original English.